Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 5.34
- Piotroski Score 6.00
- Grade Sector Perform
- Symbol (INCY)
- Company Incyte Corporation
- Price $70.37
- Changes Percentage (-0.96%)
- Change -$0.68
- Day Low $69.30
- Day High $71.40
- Year High $83.95
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/11/2025
- Fiscal Year End N/A
- Average Stock Price Target $80.50
- High Stock Price Target $200.00
- Low Stock Price Target $48.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $3.30
- Trailing P/E Ratio 17.93
- Forward P/E Ratio 17.93
- P/E Growth 17.93
- Net Income $597.60 M
Income Statement
Quarterly
Annual
Latest News of INCY
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Late Quincy Jones, Bond film producers bestowed with honorary Oscars
By Mary MillikenLOS ANGELES (Reuters) - Just weeks after his death at the age of 91, renowned music producer and composer Quincy Jones was bestowed with an honorary Oscar by Hollywood's film acade...
By Reuters | 3 days ago -
Here's How Jakafi's Patent Expiry Impacts Incyte Corporation's (INCY) Growth Prospects
Incyte Corporation is preparing for Jakafi's patent expiry in 2028, focusing on growth beyond that period. With innovative therapies and a diverse product pipeline, including Opzelura and other promis...
By Yahoo! Finance | 5 days ago -
Quincy Shares Tribute to Late Mother Kim Porter While Seemingly Shading Father Al B. Sure
Quincy Brown pays tribute to his late mother Kim Porter on her death anniversary, sharing a photo with her but excluding his father, Al B. Sure. His relationship with his father, Diddy, has been publi...
By PEOPLE.com | 5 days ago
